Efficacy and safety of oral pulmonary vasodilators in pulmonary veno-occlusive disease.
capillaries
pulmonary hypertension
treatment
vasodilation
veins
Journal
Pulmonary circulation
ISSN: 2045-8932
Titre abrégé: Pulm Circ
Pays: United States
ID NLM: 101557243
Informations de publication
Date de publication:
Oct 2022
Oct 2022
Historique:
received:
29
08
2022
revised:
15
11
2022
accepted:
02
12
2022
entrez:
16
12
2022
pubmed:
17
12
2022
medline:
17
12
2022
Statut:
epublish
Résumé
Pulmonary veno-occlusive disease (PVOD) or pulmonary capillary hemangiomatosis (PCH) is a rare subtype of pulmonary hypertension with dismal prognosis. Limited data are available on the efficacy and safety of orally administered pulmonary vasodilators for PVOD/PCH. Whether and how systemic sclerosis (SSc) affects the clinical outcomes of PVOD/PCH is also unknown. This study aimed to determine the clinical and hemodynamic efficacy and safety of oral pulmonary vasodilators for PVOD/PCH and clarify the possible effects of SSc on the clinical presentation of PVOD/PCH. We retrospectively analyzed the clinical data of 15 patients with PVOD/PCH treated with oral pulmonary vasodilators in our department since 2001. Six of them had SSc. Oral pulmonary vasodilators were administered either as single agents (
Identifiants
pubmed: 36523326
doi: 10.1002/pul2.12168
pii: PUL212168
pmc: PMC9745862
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e12168Informations de copyright
© 2022 The Authors. Pulmonary Circulation published by Wiley Periodicals LLC on behalf of the Pulmonary Vascular Research Institute.
Déclaration de conflit d'intérêts
Ichizo Tsujino, Takahiro Sato, and Satoshi Konno received research funding from Nihon Shinyaku Co., Ltd., Nippon Boehringer Ingelheim Co., Ltd., and Mochida Pharmaceutical Co., Ltd. Masaru Kato receives grants from Actelion, GlaxoSmithKline, Janssen, and Nippon Shinyaku. All other authors declare no conflicts of interest.
Références
Pulm Circ. 2022 Apr 18;12(2):e12078
pubmed: 35514782
Circ J. 2012;76(7):1729-36
pubmed: 22481098
Eur Respir J. 2019 Jan 24;53(1):
pubmed: 30545968
Eur Respir J. 2009 Aug;34(2):371-9
pubmed: 19282344
Circ J. 2019 Mar 25;83(4):842-945
pubmed: 30853682
Eur Respir J. 2015 Oct;46(4):903-75
pubmed: 26318161
Chest. 2000 Dec;118(6):1671-9
pubmed: 11115457
BMC Pulm Med. 2019 Dec 19;19(1):257
pubmed: 31856792
Medicine (Baltimore). 2008 Jul;87(4):220-233
pubmed: 18626305
Rheumatology (Oxford). 2017 Dec 1;56(12):2197-2203
pubmed: 29029203
Medicine (Baltimore). 2021 Oct 15;100(41):e27334
pubmed: 34731104
Eur Respir J. 2009 Dec;34(6):1348-56
pubmed: 19541723
Lancet Respir Med. 2017 Feb;5(2):125-134
pubmed: 28087362
Respir Investig. 2019 Mar;57(2):183-190
pubmed: 30473253
Arthritis Rheum. 2013 Nov;65(11):2737-47
pubmed: 24122180
Clin Rheumatol. 2020 May;39(5):1687-1691
pubmed: 31965379
ERJ Open Res. 2019 Feb 11;5(1):
pubmed: 30775371
Arthritis Rheum. 2012 Sep;64(9):2995-3005
pubmed: 22549387
Eur Respir J. 2016 May;47(5):1518-34
pubmed: 27009171